MedImmune Ventures Custom Case Solution & Analysis

1. Evidence Brief: MedImmune Ventures

Financial Metrics

• Total Fund Size: 400 million dollar evergreen fund established in 2002.
• Investment Capacity: Typically 5 million to 10 million dollars per deal over the life of the investment.
• Portfolio Composition: Approximately 20 to 25 active companies at any given time.
• MedImmune Revenue Context: Parent company MedImmune reported 1.2 billion dollars in annual revenue before the AstraZeneca acquisition.
• Exit Targets: Focus on Series A and B rounds with a five to seven year horizon for liquidity events.

Operational Facts

• Reporting Structure: MedImmune Ventures (MIV) reports directly to the Chief Financial Officer of MedImmune.
• Investment Committee: Comprised of the CEO, CFO, and Head of R&D.
• Geographic Focus: Primarily North America and Europe, targeting biotech hubs like Boston and San Francisco.
• Technical Due Diligence: Relies on parent company R&D staff for scientific validation of target technologies.
• Mandate: Dual focus on financial returns and strategic alignment with MedImmune core therapeutic areas: oncology, infectious disease, and respiratory health.

Stakeholder Positions

• David Mott (CEO): Views MIV as a window into external innovation and a tool for corporate development.
• MIV Investment Team: Prioritizes financial discipline and reputation within the venture capital community to maintain deal flow.
• MedImmune R&D Scientists: Often view external investments as potential threats to internal projects or additional work for due diligence without direct benefit.
• Portfolio Company Management: Value the MedImmune brand but fear loss of independence or restrictive deal terms.

Information Gaps

• Specific Internal Rate of Return (IRR) for the MIV portfolio since inception is not disclosed.
• The exact percentage of MIV portfolio companies that successfully transitioned into MedImmune licensing or acquisition deals.
• Detailed breakdown of management fees versus carry-like incentives for the MIV investment team.

2. Strategic Analysis

Core Strategic Question

• How should MedImmune Ventures balance its dual mandate of financial profitability and strategic utility to ensure it provides maximum value to the parent company without alienating the venture capital ecosystem?

Structural Analysis

The strategic tension in MIV stems from the differing objectives of corporate venture capital versus traditional institutional venture capital. Using the Strategic Value vs. Financial Return matrix, MIV currently operates in the high-financial/moderate-strategic quadrant. While this preserves its reputation with co-investors, it creates a disconnect with the parent company R&D pipeline. The core issue is the friction between the long-term nature of biotech development and the quarterly pressures of a corporate parent.

Strategic Options

Option 1: The Pipeline Extension Model. Shift focus exclusively to companies with assets that can be integrated into the MedImmune pipeline within 24 to 36 months. This requires giving R&D leadership a veto over all investments.
Trade-offs: Higher strategic relevance but significantly reduced deal flow as top-tier startups avoid restrictive corporate oversight.
Resources: Requires dedicated R&D liaisons for each portfolio company.

Option 2: The Independent Financial Model. Spin MIV off into a more autonomous unit with a primary goal of financial return, using the MedImmune name only for branding and technical validation.
Trade-offs: Maximizes financial gains and attracts top investment talent but provides minimal strategic value to the parent R&D efforts.
Resources: Requires a market-competitive carry structure for the investment team.

Option 3: The Strategic Scout Model (Recommended). Maintain the current hybrid structure but implement formal Knowledge Transfer Protocols. MIV remains financially driven but acts as an intelligence gathering arm for R&D.
Trade-offs: Balances reputation and utility but requires significant cultural change within the parent R&D organization.
Resources: Requires a structured internal platform for sharing due diligence insights with internal scientists.

Preliminary Recommendation

MedImmune should adopt the Strategic Scout Model. Financial discipline is the only way to ensure access to high-quality deals. However, the value of MIV to MedImmune is the information and early access it provides. By formalizing the information flow between MIV and R&D, the parent company can realize strategic value even from investments that do not end in acquisition.

3. Implementation Roadmap

Critical Path

• Month 1: Establish the Strategic Alignment Committee (SAC) consisting of two MIV partners and two R&D leads.
• Month 2: Implement a standardized insight report for every due diligence process to be shared with the SAC.
• Month 3: Define specific search fields for the next 12 months based on MedImmune R&D gaps.
• Month 6: Review the first cohort of investment insights for potential licensing or collaboration opportunities.

Key Constraints

• R&D Bandwidth: Internal scientists are already fully allocated; MIV due diligence is seen as a distraction.
• Confidentiality: Strict walls must exist to prevent sensitive startup data from being used by internal R&D to compete with portfolio companies.
• Incentive Misalignment: MIV team is incentivized by portfolio success; R&D is incentivized by internal project success.

Risk-Adjusted Implementation Strategy

To mitigate R&D resistance, MedImmune must allocate a specific budget for internal scientists who assist MIV. This budget covers the time spent on due diligence, ensuring it is not a tax on their existing projects. To address confidentiality, MIV will use clean rooms for data sharing, ensuring that only non-proprietary strategic insights reach the broader R&D team until a formal partnership is explored. This phased approach ensures that MIV remains a welcome partner in the VC world while increasing its internal utility.

4. Executive Review and BLUF

BLUF

MedImmune Ventures must prioritize its role as a strategic intelligence engine. The current model produces financial gains but fails to bridge the gap between external innovation and internal R&D needs. By formalizing knowledge transfer and aligning incentives between the fund and the parent R&D department, MedImmune can secure a competitive advantage in pipeline development. The fund should remain financially disciplined to maintain its position in the venture community, but its success should be measured by the strategic options it creates for the parent company.

Dangerous Assumption

The most consequential unchallenged premise is that MedImmune R&D has the capacity and willingness to absorb external innovation. If the internal culture remains resistant to technologies not invented here, then any strategic investment, no matter how successful financially, will fail to impact the parent company long-term health.

Unaddressed Risks

Unconsidered Alternative

The analysis overlooks the possibility of MedImmune Ventures becoming a lead investor rather than a co-investor. By taking lead positions, MIV could exert more influence over the strategic direction of portfolio companies and secure more favorable rights for the parent company, albeit at the cost of higher risk and higher capital concentration per deal.

Verdict

APPROVED FOR LEADERSHIP REVIEW